Simcere Pharmaceutical Group Ltd
S2P
Company Profile
Business description
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
Contact
No. 699-18, Xuanwu Road
Xuanwu District
Jiangsu Province
Nanjing210042
CHNT: +86 2585566666
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
7,038
Stocks News & Analysis
stocks
What happens if Tesla and SpaceX merge?
We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.
stocks
Chart of the Week: Is CSL finally turning the ship around?
The beaten down healthcare giant remains cheap on turnaround potential.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,836.70 | 71.20 | 0.81% |
| CAC 40 | 8,200.80 | 38.97 | 0.48% |
| DAX 40 | 24,209.71 | 14.40 | 0.06% |
| Dow JONES (US) | 50,848.75 | 929.97 | 1.86% |
| FTSE 100 | 10,303.88 | 49.07 | 0.48% |
| HKSE | 24,249.29 | 158.67 | -0.65% |
| NASDAQ | 25,809.66 | 640.16 | 2.54% |
| Nikkei 225 | 64,217.27 | 38.00 | 0.06% |
| NZX 50 Index | 13,269.70 | 67.54 | 0.51% |
| S&P 500 | 7,394.30 | 127.31 | 1.75% |
| S&P/ASX 200 | 8,633.20 | 69.70 | 0.81% |
| SSE Composite Index | 3,987.01 | 6.21 | -0.16% |